Professional Education

  • Master of Science, Universite Paul Sabatier (2011)
  • Doctor of Pharmacy, Universite Paul Sabatier (2015)
  • Doctor of Philosophy, Universite Paul Sabatier (2015)

Stanford Advisors


All Publications

  • CD81 is a novel immunotherapeutic target for B cell lymphoma. The Journal of experimental medicine Vences-Catalan, F., Kuo, C., Rajapaksa, R., Duault, C., Andor, N., Czerwinski, D. K., Levy, R., Levy, S. 2019


    The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.

    View details for DOI 10.1084/jem.20190186

    View details for PubMedID 31123084

  • IL-33-expanded human V gamma 9V delta 2 T cells have anti-lymphoma effect in a mouse tumor model EUROPEAN JOURNAL OF IMMUNOLOGY Duault, C., Betous, D., Bezombes, C., Roga, S., Cayrol, C., Girard, J., Fournie, J., Poupot, M. 2017; 47 (12): 2137?41


    From several years, the anticancer effects of V?9 T lymphocytes make these cells good candidates for cancer immunotherapies. However, the proved efficacy of ??á? cell-based cancer immunotherapies in some clinical trials was minimized due to the inherent toxicity of IL-2, which is essential for the combination therapy with Phosphoantigen (PAg). Recently, we showed that IL-33, a ? chain receptor-independent cytokine, was able to induce the in vitro proliferation of PAg-activated V?9 Tácells, which were fully functional expressing IFN-? and TNF-? and showing in vitro anti-tumor cytotoxicity. We proposed IL-33 as an alternative to IL-2 for V?9 Tácell-based cancer immunotherapies, and have therefore evaluated the efficacy of this cytokine in preclinical investigations. This study shows that human V?9 Tácells are able to proliferate in a mouse model with the combination of PAg and rhIL-33, and that IL-33-expanded V?9 Tácells can prevent tumor growth in a mouse lymphoma model.

    View details for PubMedID 28741710

  • CD81 as a tumor target. Biochemical Society transactions Vences-Catalßn, F., Duault, C., Kuo, C., Rajapaksa, R., Levy, R., Levy, S. 2017; 45 (2): 531-535


    CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell-cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform. CD81 has also been shown to regulate cell migration and invasion, and has therefore been implicated in cancer progression. Indeed, we have recently shown that CD81 contributes to tumor growth and metastasis. CD81 is expressed in most types of cancer, including breast, lung, prostate, melanoma, brain cancer and lymphoma, and the overexpression or down-regulation of this molecule has been correlated with either good or bad prognosis. Here, we discuss the role of CD81 in cancer and its potential therapeutic use as a tumor target.

    View details for DOI 10.1042/BST20160478

    View details for PubMedID 28408492

Footer Links:

Stanford Medicine Resources: